As a result, the HR of SETD4 was calculated for OS and PFS in various cancer types, revealing that SETD4 upregulation poses a risk for poor OS in ACC, KIRC, and PCPG and a risk for worse PFS in PRAD, ACC, LIHC, and UVM. This evidence concerns the gene SETD4 and cancer.